Drug Profile
Mepacrine
Alternative Names: 9-aminoacridine; Atabrine dihydrochloride; CBL 0102; Curaxin CBL0102; Quinacrine; SN 390Latest Information Update: 02 Sep 2021
Price :
$50
*
At a glance
- Originator Cleveland BioLabs
- Developer Incuron; National Cancer Institute (USA)
- Class Aminoacridines; Antimalarials; Antineoplastics; Antiprotozoals; Small molecules
- Mechanism of Action SSRP1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Prostate cancer
- No development reported Liver cancer; Liver metastases; Non-small cell lung cancer
Most Recent Events
- 01 Sep 2021 Cytocom is now called Statera BioPharma
- 28 Jul 2021 Cytocom has been merged with Cleveland BioLabs to form Cytocom
- 28 May 2018 No recent reports of development identified for phase-I development in Liver metastases in Russia (PO)